MAIA Biotechnology, Inc., (NYSE American: MAIA) ('MAIA”, the 'Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has ...
BOSTON, MA / ACCESS Newswire / March 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company ...
Vladimir Putin took part in the plenary session of the Future Technologies Forum. The discussion theme is Bioeconomy for ...
Life Sciences Investors delivered a 40.59% NAV return in 2025, supported by innovation-focused biotechnology. Read the full ...
Delve into the field of pulmonary hypertension as GSK places a $950M bet on 35Pharma's candidate HS235 following the footsteps of Winrevair.
T Biosciences, an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, ...
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2025 Earnings Call Transcript February 26, 2026 Nautilus Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.14 ...
Milestone marks the first clinical program for Charcot-Marie-Tooth disease and Vanishing White Matter disease. SAN FRANCISCO and SHANGHAI, /PRNewswire/ -- ReviR Therapeutics, a clinical-stage biotechn ...
Analysts consider AtaiBeckley’s MDMA candidate a “high-risk, high-reward” bet after the drug demonstrated reductions in ...
14h
VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.
VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies, today announced that its shareholders approved the merger between VERAXA and ...
Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results